/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Viking Therapeutics, Inc. Share Price Today: Live Updates & Key Insights

Viking Therapeutics, Inc. share price today is $35.65, up -0.81%. The stock opened at $35.9 against the previous close of $35.76, with an intraday high of $36.13 and low of $34.57.

Viking Therapeutics, Inc. Share Price Chart

style
pb-0

Viking Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Viking Therapeutics, Inc. Share Price Performance

$35.65 -0.0081(-0.81%) VKTX at 13 Mar 2026 03:46 PM Biotechnology
Lowest Today 34.57
Highest Today 36.13
Today’s Open 35.9
Prev. Close 35.76
52 Week High 43.15
52 Week Low 18.92
Day’s Range: Low 34.57 High 36.13
52-Week Range: Low 18.92 High 43.15
1 day return -
1 Week return +7.54
1 month return +22.25
3 month return -1.79
6 month return +47.29
1 year return +19.33
3 year return +237.03
5 year return +432.88
10 year return -

Viking Therapeutics, Inc. Institutional Holdings

Vanguard Group Inc 8.64

FMR Inc 5.68

BlackRock Inc 4.84

JPMorgan Chase & Co 4.46

State Street Corp 3.91

Morgan Stanley - Brokerage Accounts 3.23

Vanguard Total Stock Mkt Idx Inv 2.93

State Street® SPDR® S&P® Biotech ETF 2.23

Two Sigma Investments LLC 2.11

Vanguard Small Cap Index 2.11

Two Sigma Advisers, LLC 1.84

Susquehanna International Group, LLP 1.82

Ameriprise Financial Inc 1.81

Citadel Advisors Llc 1.64

D. E. Shaw & Co LP 1.49

Geode Capital Management, LLC 1.39

Vanguard Small Cap Growth Index Inv 1.17

UBS Group AG 1.16

Jupiter Merian Glb Eq AbsRet I USD Acc 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.06

Fidelity Advisor Growth Opps M 0.92

BNP Paribas Arbitrage, SA 0.86

CT (Lux) American Smaller Com 9U USD 0.76

TANG CAPITAL MANAGEMENT LLC 0.75

Jane Street Group LLC 0.69

Pictet Asset Manangement SA 0.65

Artia Global Partners LP 0.62

Charles Schwab Investment Management Inc 0.61

Fidelity Select Health Care 0.58

Fidelity Advisor Biotechnology I 0.56

State St Russell Sm/Mid Cp® Indx SL Cl I 0.54

Fidelity Extended Market Index 0.51

Fidelity Stock Selector Small Cap 0.48

Schwab US Small-Cap ETF™ 0.47

CT American Smaller Coms(US) InstAccGBP 0.43

Pictet-Biotech P USD 0.41

Fidelity Series Small Cap Opps 0.40

Vanguard Explorer Inv 0.38

BlackRock Health Sciences Opps Inv A 0.37

Fidelity Select Biotechnology 0.37

Viking Therapeutics, Inc. Market Status

Strong Buy: 10

Buy: 7

Hold: 2

Sell: 0

Strong Sell: 0

Viking Therapeutics, Inc. Fundamentals

Market Cap 4132.22 M

PB Ratio 6.4661

PE Ratio 0.0

Enterprise Value 3426.62 M

Total Assets 715.73 M

Volume 2144139

Viking Therapeutics, Inc. Company Financials

Annual Revenue FY25:0 0.0M, FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:10701 0.0M

Annual Profit FY25:-431000 -0.4M, FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-359639000 -359.6M, FY24:-109963000 -110.0M, FY23:-80849000 -80.8M, FY22:-67379000 -67.4M, FY21:-54002000 -54.0M

Quarterly Revenue Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q4/2025:-94000 -0.1M, Q3/2025:-114000 -0.1M, Q2/2025:-112000 -0.1M, Q1/2025:null 0.0M, Q3/2024:-87000 -0.1M

Quarterly Net worth Q4/2025:-157662000 -157.7M, Q3/2025:-90787000 -90.8M, Q2/2025:-65561000 -65.6M, Q1/2025:-45629000 -45.6M, Q3/2024:-24940000 -24.9M

About Viking Therapeutics, Inc. & investment objective

Company Information Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 53

Industry Biotechnology

CEO Dr. Brian Lian Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow